Cargando…

Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance

BACKGROUND: Cardiovascular complications of obesity and diabetes are major health problems. Assessing their development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The aim of this study was to longitudinally investigate cardiac alteration...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdesselam, Inès, Pepino, Pauline, Troalen, Thomas, Macia, Michael, Ancel, Patricia, Masi, Brice, Fourny, Natacha, Gaborit, Bénédicte, Giannesini, Benoît, Kober, Frank, Dutour, Anne, Bernard, Monique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636800/
https://www.ncbi.nlm.nih.gov/pubmed/26546347
http://dx.doi.org/10.1186/s12968-015-0198-x
_version_ 1782399706816577536
author Abdesselam, Inès
Pepino, Pauline
Troalen, Thomas
Macia, Michael
Ancel, Patricia
Masi, Brice
Fourny, Natacha
Gaborit, Bénédicte
Giannesini, Benoît
Kober, Frank
Dutour, Anne
Bernard, Monique
author_facet Abdesselam, Inès
Pepino, Pauline
Troalen, Thomas
Macia, Michael
Ancel, Patricia
Masi, Brice
Fourny, Natacha
Gaborit, Bénédicte
Giannesini, Benoît
Kober, Frank
Dutour, Anne
Bernard, Monique
author_sort Abdesselam, Inès
collection PubMed
description BACKGROUND: Cardiovascular complications of obesity and diabetes are major health problems. Assessing their development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The aim of this study was to longitudinally investigate cardiac alterations and ectopic fat accumulation associated with diet-induced obesity using multimodal cardiovascular magnetic resonance (CMR) in mice. The second objective was to monitor cardiac response to exendin-4 (GLP-1 receptor agonist). METHODS: Male C57BL6R mice subjected to a high fat (35 %) high sucrose (34 %) (HFHSD) or a standard diet (SD) during 4 months were explored every month with multimodal CMR to determine hepatic and myocardial triglyceride content (HTGC, MTGC) using proton MR spectroscopy, cardiac function with cine cardiac MR (CMR) and myocardial perfusion with arterial spin labeling CMR. Furthermore, mice treated with exendin-4 (30 μg/kg SC BID) after 4 months of diet were explored before and 14 days post-treatment with multimodal CMR. RESULTS: HFHSD mice became significantly heavier (+33 %) and displayed glucose homeostasis impairment (1-month) as compared to SD mice, and developed early increase in HTGC (1 month, +59 %) and MTGC (2-month, +63 %). After 3 months, HFHSD mice developed cardiac dysfunction with significantly higher diastolic septum wall thickness (sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm) and lower cardiac index (0.45 ± 0.06 mL/min/g vs. 0.68 ± 0.07 mL/min/g, p = 0.02) compared to SD mice. A significantly lower cardiac perfusion was also observed (4 months:7.5 ± 0.8 mL/g/min vs. 10.0 ± 0.7 mL/g/min, p = 0.03). Cardiac function at 4 months was negatively correlated to both HTGC and MTGC (p < 0.05). 14-day treatment with Exendin-4 (Ex-4) dramatically reversed all these alterations in comparison with placebo-treated HFHSD. Ex-4 diminished myocardial triglyceride content (−57.8 ± 4.1 %), improved cardiac index (+38.9 ± 10.9 %) and restored myocardial perfusion (+52.8 ± 16.4 %) under isoflurane anesthesia. Interestingly, increased wall thickness and hepatic steatosis reductions were independent of weight loss and glycemia decrease in multivariate analysis (p < 0.05). CONCLUSION: CMR longitudinal follow-up of cardiac consequences of obesity and diabetes showed early accumulation of ectopic fat in mice before the occurrence of microvascular and contractile dysfunction. This study also supports a cardioprotective effect of glucagon-like peptide-1 receptor agonist. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12968-015-0198-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4636800
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46368002015-11-12 Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance Abdesselam, Inès Pepino, Pauline Troalen, Thomas Macia, Michael Ancel, Patricia Masi, Brice Fourny, Natacha Gaborit, Bénédicte Giannesini, Benoît Kober, Frank Dutour, Anne Bernard, Monique J Cardiovasc Magn Reson Research BACKGROUND: Cardiovascular complications of obesity and diabetes are major health problems. Assessing their development, their link with ectopic fat deposition and their flexibility with therapeutic intervention is essential. The aim of this study was to longitudinally investigate cardiac alterations and ectopic fat accumulation associated with diet-induced obesity using multimodal cardiovascular magnetic resonance (CMR) in mice. The second objective was to monitor cardiac response to exendin-4 (GLP-1 receptor agonist). METHODS: Male C57BL6R mice subjected to a high fat (35 %) high sucrose (34 %) (HFHSD) or a standard diet (SD) during 4 months were explored every month with multimodal CMR to determine hepatic and myocardial triglyceride content (HTGC, MTGC) using proton MR spectroscopy, cardiac function with cine cardiac MR (CMR) and myocardial perfusion with arterial spin labeling CMR. Furthermore, mice treated with exendin-4 (30 μg/kg SC BID) after 4 months of diet were explored before and 14 days post-treatment with multimodal CMR. RESULTS: HFHSD mice became significantly heavier (+33 %) and displayed glucose homeostasis impairment (1-month) as compared to SD mice, and developed early increase in HTGC (1 month, +59 %) and MTGC (2-month, +63 %). After 3 months, HFHSD mice developed cardiac dysfunction with significantly higher diastolic septum wall thickness (sWtnD) (1.28 ± 0.03 mm vs. 1.12 ± 0.03 mm) and lower cardiac index (0.45 ± 0.06 mL/min/g vs. 0.68 ± 0.07 mL/min/g, p = 0.02) compared to SD mice. A significantly lower cardiac perfusion was also observed (4 months:7.5 ± 0.8 mL/g/min vs. 10.0 ± 0.7 mL/g/min, p = 0.03). Cardiac function at 4 months was negatively correlated to both HTGC and MTGC (p < 0.05). 14-day treatment with Exendin-4 (Ex-4) dramatically reversed all these alterations in comparison with placebo-treated HFHSD. Ex-4 diminished myocardial triglyceride content (−57.8 ± 4.1 %), improved cardiac index (+38.9 ± 10.9 %) and restored myocardial perfusion (+52.8 ± 16.4 %) under isoflurane anesthesia. Interestingly, increased wall thickness and hepatic steatosis reductions were independent of weight loss and glycemia decrease in multivariate analysis (p < 0.05). CONCLUSION: CMR longitudinal follow-up of cardiac consequences of obesity and diabetes showed early accumulation of ectopic fat in mice before the occurrence of microvascular and contractile dysfunction. This study also supports a cardioprotective effect of glucagon-like peptide-1 receptor agonist. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12968-015-0198-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-06 /pmc/articles/PMC4636800/ /pubmed/26546347 http://dx.doi.org/10.1186/s12968-015-0198-x Text en © Abdesselam et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Abdesselam, Inès
Pepino, Pauline
Troalen, Thomas
Macia, Michael
Ancel, Patricia
Masi, Brice
Fourny, Natacha
Gaborit, Bénédicte
Giannesini, Benoît
Kober, Frank
Dutour, Anne
Bernard, Monique
Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title_full Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title_fullStr Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title_full_unstemmed Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title_short Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance
title_sort time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after glp-1 analog treatment using multimodal cardiovascular magnetic resonance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636800/
https://www.ncbi.nlm.nih.gov/pubmed/26546347
http://dx.doi.org/10.1186/s12968-015-0198-x
work_keys_str_mv AT abdesselamines timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT pepinopauline timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT troalenthomas timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT maciamichael timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT ancelpatricia timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT masibrice timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT fournynatacha timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT gaboritbenedicte timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT giannesinibenoit timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT koberfrank timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT dutouranne timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance
AT bernardmonique timecourseofcardiometabolicalterationsinahighfathighsucrosedietmicemodelandimprovementafterglp1analogtreatmentusingmultimodalcardiovascularmagneticresonance